Publications

Clinical Trial, Phase I
Journal Article Randomized Controlled Trial
Ppublish 40 citations
Electronic publication date
December 20, 2018

View on Pubmed.gov 30054895 | View on doi.org 10.1007/s40268-...

Population Pharmacokinetic Modelling of Ceftazidime and Avibactam in the Plasma and Epithelial Lining Fluid of Healthy Volunteers.

Search for publications in this journal Drugs R D - 18(3):221-230

Abstract

OBJECTIVES

Our objective was to develop population pharmacokinetic (PK) models for ceftazidime and avibactam in the plasma and epithelial lining fluid (ELF) of healthy volunteers and to compare ELF concentrations to plasma PK/pharmacodynamic (PD) targets.

METHODS

Plasma and ELF population PK models were developed for ceftazidime and avibactam concentration data from 42 subjects (NCT01395420). Two- and three-compartment plasma PK models were fitted to ceftazidime and avibactam plasma PK data, and different plasma-ELF linked models were evaluated. Using best-fitting models, plasma and ELF concentration-time profiles were simulated for 1000 subjects. ELF concentration-time profiles for ceftazidime/avibactam 2000-500 mg every 8 h were compared with plasma PK/PD targets for ceftazidime (50% of time above [fT >] 8 mg/l) and avibactam (50% fT > 1 mg/l).

RESULTS

Three-compartment PK models best fitted the plasma concentration data for ceftazidime and avibactam. ELF data for both drugs were best described by a direct response (instantaneous equilibrium) model. Ceftazidime plasma-ELF relationships were best described by a saturable Michaelis-Menten model. For avibactam, departure from plasma-ELF relationship linearity was more modest than for ceftazidime. ELF:plasma penetration ratios of both ceftazidime (52%) and avibactam (42%) at plasma concentrations relevant for efficacy (~ 8 mg/l for ceftazidime and ~ 1 mg/l for avibactam) were greater than previously calculated using non-compartmental area under the curve (AUC) methods, which average across the entire concentration range. Ceftazidime and avibactam ELF exposures exceeded their respective plasma PK/PD time-above-threshold targets by the dosing interval mid-point in most subjects.

CONCLUSIONS

This compartmental modelling analysis suggests ELF exposures of both ceftazidime and avibactam exceed levels required for efficacy in plasma.

References

Lancet Infect Dis. 2018 Mar;18(3):285-295

Antimicrob Agents Chemother. 2014 Jun;58(6):3366-72

Antimicrob Agents Chemother. 2012 Mar;56(3):1606-8

Clin Infect Dis. 2010 Aug 1;51 Suppl 1:S103-10

Cited by 40 citations (total)

Journal Article Review

Pharmacokinetics of Non-β-Lactam β-Lactamase Inhibitors.

Electronic publication date July 3, 2021

Search for publications in this journal Antibiotics (Basel)

Giacomo Luci [...] Antonello Di Paolo et al.

The growing emergence of drug-resistant bacterial strains is an issue to treat severe infections, and many efforts have identified new...

Journal Article

Evaluation of Susceptibility Testing Methods for Aztreonam and Ceftazidime-Avibactam Combination Therapy on Extensively Drug-Resistant Gram-Negative Organisms.

Electronic publication date November 3, 2021

Search for publications in this journal Antimicrob Agents Chemother

Ayesha Khan [...] Micah M Bhatti et al.

Carbapenem-resistant (CRE) and Pseudomonas aeruginosa (CR-PA) producing metallo-β-lactamases (MBLs) cause severe nosocomial infections with no defined treatment. The combination...

Conflict of interest statement

No conflict of interest statement provided.

MeSH

Specialties

Substances